You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

ZEJULA (niraparib) may keep you moving forward

ZEJULA is a maintenance treatment for women with advanced ovarian cancer after complete or partial response to platinum-based chemotherapy.  

If You've Been Recently Diagnosed With Advanced Ovarian Cancer, ZEJULA (niraparib) May Offer You a Choice About What Comes Next in Your Treatment Journey

ZEJULA is a once-daily, oral medicine used for the maintenance treatment of women with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer.

ZEJULA is the first and only once-daily PARP inhibitor used after the cancer has responded (complete or partial response) to treatment with platinum-based chemotherapy.1-3
See below for full Indication.

First-line maintenance treatment with ZEJULA may offer you more time without your ovarian cancer recurring1,4

The PRIMA clinical trial included 733 women with advanced ovarian cancer who responded (complete or partial response) to first-line platinum-based chemotherapy. The trial included women with and without a positive test result for certain genetic characteristics (ie, homologous recombination deficiency, or HRD). The HRD-positive group included women who were BRCA-positive.

The trial measured median progression-free survival, or mPFS. PFS means the length of time during and after treatment that you live with cancer but it does not get worse. Median is the middle number in a set of data, also called the midpoint. It means that half of the numbers are greater than the median and half are less.1,4-7

 

Overall study population (733 women)1

HRD-positive group (373 women)1


Women taking ZEJULA had less risk of disease progression1,4

In the overall study population, ZEJULA reduced the risk of progression by 38% compared with placebo

In HRD-positive women, ZEJULA reduced the risk of progression by 57% compared with placebo


ZEJULA is approved as maintenance treatment for women with and without a positive test for BRCA or HRD1,4

The safety profile of ZEJULA in the PRIMA trial was consistent with previous clinical trials that studied ZEJULA.1,4

The most common adverse reactions in PRIMA included low red blood cells; low platelets; low white blood cells; nausea; vomiting; constipation; tiredness; changes in liver function and other blood tests; decreased appetite; pain in the joints, muscles and back; headache; dizziness; trouble sleeping; changes in the amount or color of the urine; shortness of breath; cough; and high blood pressure. Due to an adverse reaction, 12% of women stopped treatment with ZEJULA and 2.5% stopped treatment with placebo. These are not the only side effects associated with ZEJULA.

Please see Side Effects to learn more or Important Safety Information below to learn more.

ZEJULA My Way

ZEJULA My Way is a patient support program filled with information, guidance, and tools you can use as you take an active role in your treatment.

Sign up today

TOGETHER with GSK ONCOLOGY

Patient Reimbursement
Support

Our Commercial Co-pay Assistance program may reduce your copay and/or coinsurance to as little as $0 with a $26,000 annual maximum if you have commercial insurance

LEARN MORE

Recurrent
Ovarian Cancer

Get more information about what recurrent ovarian cancer might mean for you

Understand Recurrent Ovarian Cancer

Maintenance and
Treatment with ZEJULA

Discover the outcomes of ZEJULA clinical trials

SEE CLINICAL TRIAL RESULTS

Support
During Treatment

Find resources and information that may help you access ZEJULA

Get Access and Support
Back to Top